Structural changes in airway diseases - Characteristics, mechanisms, consequences, and pharmacologic modulation

被引:156
作者
Bergeron, C [1 ]
Boulet, LP [1 ]
机构
[1] Univ Laval, Hop Laval, Ctr Rech, Inst Cardiol & Pneumol, Quebec City, PQ G1V 4C5, Canada
关键词
airway inflammation; airway remodeling; antiasthmatic therapy; asthma; COPD; corticosteroids; cystic fibrosis;
D O I
10.1378/chest.129.4.1068
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
In airway diseases such as asthma and COPD, specific structural changes may be observed very likely secondary to an underlying inflammatory process. Although it is still controversial, airway remodeling may contribute to the development of these diseases and to their clinical expression and outcome. Airway remodeling has been described in asthma in various degrees of severity, and correlations have been found between such features as increase in subepithelial collagen or proteoglyean deposits and airway responsiveness. Although the clinical significance of airway remodeling remains a matter of debate, it has been suggested as a potential target for treatments aimed at reducing asthma severity, improving its control, and possibly preventing its development. To date, drugs used to treat airway diseases have a little influence on airway structural changes. More research should be done to identify key changes, valuable treatments, and proper interventional timing to counteract these changes. The potential of novel therapeutic agents to reverse or prevent airway remodeling is an exciting avenue and warrants further evaluation.
引用
收藏
页码:1068 / 1087
页数:20
相关论文
共 256 条
[71]  
FINE A, 1987, J BIOL CHEM, V262, P3897
[72]   Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics [J].
Flood-Page, P ;
Menzies-Gow, A ;
Phipps, S ;
Ying, S ;
Wangoo, A ;
Ludwig, MS ;
Barnes, N ;
Robinson, D ;
Kay, AB .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (07) :1029-1036
[73]   Interleukins-4,-5, and-13: emerging therapeutic targets in allergic disease [J].
Foster, PS ;
Martinez-Moczygemba, M ;
Huston, DP ;
Corry, DB .
PHARMACOLOGY & THERAPEUTICS, 2002, 94 (03) :253-264
[74]   Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex [J].
Fujita, J ;
Ohtsuki, Y ;
Shigeto, E ;
Suemitsu, I ;
Yamadori, I ;
Bandoh, S ;
Shiode, M ;
Nishimura, K ;
Hirayama, T ;
Matsushima, T ;
Fukunaga, H ;
Ishida, T .
RESPIRATORY MEDICINE, 2003, 97 (08) :933-938
[75]   In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling [J].
Fujitani, Y ;
Trifilieff, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (02) :193-198
[76]   Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis [J].
Gaga, M ;
Bentley, AM ;
Humbert, M ;
Barkans, J ;
O'Brien, F ;
Wathen, CG ;
Kay, AB ;
Durham, SR .
THORAX, 1998, 53 (08) :685-691
[77]  
GAUTRIN D, 1999, REACTIVE AIRWAYS DYS
[78]  
Gelfand EW, 1996, CLIN EXP IMMUNOL, V104, P1
[79]   The development of gene therapy for diseases of the lung [J].
Gill, DR ;
Davies, LA ;
Pringle, IA ;
Hyde, SC .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (03) :355-368
[80]   Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue [J].
Gizycki, MJ ;
Hattotuwa, KL ;
Barnes, N ;
Jeffery, PK .
THORAX, 2002, 57 (09) :799-803